Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-09-03

Clinical Trial Update: Neoadjuvant Ipilimumab in Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of ipilimumab in prostate cancer has completed enrollment and posted results as of September 3, 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ipilimumab (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-09-03